Payment overview · 2025
General Payments
$794.98
52 reported records · 15 companies
Healthcare provider profile · identity verified
Janey P Phipps, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LONDON, KY · NPI 1245328319
Verified facts
What the public records show
CMS Open Payments records show Janey P Phipps, APRN received $794.98 in general payments during 2025 across 52 reported records.
Novo Nordisk Inc accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.41 | 20.9% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.61 | 19.8% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.87 | 13.3% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.77 | 8.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $63.16 | 7.9% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $39.24 | 4.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.74 | 4.8% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $32.72 | 4.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.75 | 2.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.10 | 2.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.20 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.78 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.64 | 2.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.35 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.64 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.98 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.42 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $133.92 | 12 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $105.87 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $71.24 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.77 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $63.16 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.42 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.74 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $32.72 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.05 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $11.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $8.16 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $8.16 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 280 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 37 |
| Losartan Potassium | Losartan Potassium | 171 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 41 |
| Metformin Hcl | Metformin Hcl | 158 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 146 | 45 |
| Omeprazole | Omeprazole | 143 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 33 |
| Lisinopril | Lisinopril | 117 | 36 |
| Potassium Chloride | Potassium Chloride | 113 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 31 |
| Clonazepam | Clonazepam | 97 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 21 |
| Ibuprofen | Ibuprofen | 89 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 11 |
| Alprazolam | Alprazolam | 88 | 12 |
| Famotidine | Famotidine | 84 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 28 |
| Ozempic | Semaglutide | 80 | 16 |
| Atenolol | Atenolol | 78 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 16 |
| Mounjaro | Tirzepatide | 74 | 15 |
| Alendronate Sodium | Alendronate Sodium | 72 | 17 |
| Tramadol Hcl | Tramadol Hcl | 72 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 16 |
| Buspirone Hcl | Buspirone Hcl | 69 | 17 |
| Montelukast Sodium | Montelukast Sodium | 67 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 19 |
| Furosemide | Furosemide | 64 | 21 |
| Sertraline Hcl | Sertraline Hcl | 62 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 62 | 17 |
| Methylprednisolone | Methylprednisolone | 58 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 16 |
| Jardiance | Empagliflozin | 52 | 14 |
| Glimepiride | Glimepiride | 51 | 16 |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Simvastatin | Simvastatin | 48 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 15 |
| Carvedilol | Carvedilol | 40 | 13 |
| Ondansetron Odt | Ondansetron | 39 | suppressed |
| Allopurinol | Allopurinol | 37 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 14 |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Eliquis | Apixaban | 34 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 26 |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 14 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Meloxicam | Meloxicam | 29 | 14 |
| Nystatin | Nystatin | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 16 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Diazepam | Diazepam | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.98 · 52 records | Novo Nordisk Inc | CREON, FREESTYLE LIBRE 3, IBSRELA, Korlym, LEQVIO, LINZESS, MAVYRET, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REZDIFFRA, Rybelsus, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error